Myocardial Inflammation in Systemic Lupus Erythematosus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01761422

Enrollment

Registered

2013-01-04

Start date

2012-07-01

Completion date

2026-11-01

Last updated

2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SLE

Brief summary

The goal is to assess for myocardial edema on cardiac MRI during SLE flare to assess for myocardial inflammation.

Detailed description

The over-arching goal of this work is to further the understanding of myocardial damage in systemic lupus erythematosus (SLE) using state of the art CV imaging to investigate a novel potential mechanism of CV injury in SLE, subclinical myocardial inflammation. Aim 1: Investigate an alternative pathway for CV morbidity in SLE by measuring myocardial edema at time of moderate to severe flare and compare values to post-flare studies and historical healthy controls. Hypothesis 1: Myocardial edema, measured quantitatively with T2 CMR mapping during moderate to severe SLE flare will be significantly increased compared to 1) historical controls and 2) in SLE patients after resolution of flare. Aim 2: Perform exploratory analyses investigating relationships between myocardial edema on CMR and markers of SLE disease activity and CV risk factors. Hypothesis 2: Markers of disease activity including inflammatory makers (ESR and high sensitivity c-reactive protein), complement and autoantibody levels will predict the presence of T2 CMR detected myocardial edema during flare.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* • Diagnosis of SLE by American College of Rheumatology Classification Criteria \[21\] * Active SLE Flare defined by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)\[22\] \> 6 or British Isles Lupus Assessment Group (BILAG) Index A or B.\[23\]

Exclusion criteria

* Pregnant * Allergy to gadolinium * Severe claustrophobia * Renal replacement therapy or glomerular filtration rate (GFR) \< 30 mL/min/1.75m² * Medically unstable for transportation to Ross MRI scanner. Stability will be defined as: not on mechanical ventilation, HR \< 120 BPM, MAP \> 65 mmHg. The treating providers' input on the patient's stability will also be considered in addition to these criteria * Weight \> 500 pounds * MR incompatible implanted devices such as neurostimulator pacemakers and implantable defibrillators, presence of intracranial metal or any metal not compatible with CMR

Design outcomes

Primary

Measure	Time frame	Description
T2 edema on Cardiac MRI	3 months	Compare T2 edema at flare and 3 months later

Countries

United States

Outcome results